Myriad Genetics, Inc. (MYGN) — Stock Score Summary

Myriad Genetics, Inc. (MYGN) has a MoatMap StockRank of 24/100 based on Quality (39/100), Value (48/100), and Momentum (24/100) factor scores. The current signal is SELL. Myriad Genetics, Inc., a US healthcare company focused on genetic testing, does not have a clear, compelling connection to any of the identified macro themes. The 'STRONG_SELL' signal suggests underlying fundamental issues or valuation concerns that are not offset by a powerful macro tailwind.

Myriad Genetics, Inc. is a leading genetic testing and precision medicine company focused on developing and commercializing tests for cancer risk assessment, prognosis, and treatment selection. Its competitive advantage lies in a robust portfolio of proprietary diagnostic tests, extensive genomic database, and strong intellectual property, making it a pioneer in personalized healthcare.

Key Financial Metrics

Price$4.22
Market Cap$399M
P/E (Forward)24.06
Price/Book1.08
Return on Equity-23.5%
Return on Invested Capital-67.1%
Debt/Equity32.84
Gross Margin68.1%
Operating Margin-21.4%
Revenue Growth-20.8%
Free Cash Flow$-46M

Myriad Genetics, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Myriad Genetics, Inc.’s (MYGN) StockRank?
MoatMap’s StockRank for Myriad Genetics, Inc. (MYGN) is 24/100, with a Sell signal. It is a composite of Quality (39), Value (48), and Momentum (24) factor ranks across MoatMap’s 19,000+ stock universe.
Does Myriad Genetics, Inc. have an economic moat?
Myriad Genetics, Inc. (MYGN) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Myriad Genetics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Myriad Genetics, Inc. (MYGN) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Myriad Genetics, Inc. in?
Myriad Genetics, Inc. (MYGN) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksMYGN deep dive reportAI ChampionsHow we score stocksSense-check another stock